Toxicologic study of anthralin in an aqueous cream formulation.
A group of forty-eight patients with psoriasis who were being treated with anthralin cream were examined for side effects. Based on the variables investigated, there was no evidence of any systemic toxicity or excretion of anthraquinones (detection limit 20 micrograms/ml), while clinically, patients were seen to respond satisfactorily.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000873:Anthracenes / Q000009:adverse effects*; D000875:Anthralin / Q000009:adverse effects* / Q000627:therapeutic use; D001806:Blood Urea Nitrogen; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*
D000873:Anthracenes; D000875:Anthralin